Belite Bio, Inc
BLTE
$148.60
-$3.19-2.10%
NASDAQ
| 09/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 15.21M | 13.10M | 13.10M | 12.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 47.12M | 42.62M | 42.62M | 43.84M |
| Operating Income | -- | -47.12M | -42.62M | -42.62M | -43.84M |
| Income Before Tax | -- | -42.96M | -39.86M | -39.86M | -42.11M |
| Income Tax Expenses | -- | 6.00K | 5.00K | 5.00K | 6.00K |
| Earnings from Continuing Operations | -- | -42.97 | -39.86 | -39.86 | -42.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -42.97M | -39.86M | -39.86M | -42.12M |
| EBIT | -- | -47.12M | -42.62M | -42.62M | -43.84M |
| EBITDA | -- | -46.97M | -42.48M | -42.47M | -43.72M |
| EPS Basic | -- | -1.37 | -1.30 | -1.30 | -1.41 |
| Normalized Basic EPS | -- | -0.38 | -0.15 | -0.33 | -0.15 |
| EPS Diluted | -- | -1.37 | -1.30 | -1.30 | -1.41 |
| Normalized Diluted EPS | -- | -0.38 | -0.15 | -0.33 | -0.15 |
| Average Basic Shares Outstanding | -- | 124.41M | 121.27M | 121.27M | 117.89M |
| Average Diluted Shares Outstanding | -- | 124.41M | 121.27M | 121.27M | 117.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |